TAG:
Elizabeth Holmes
Elizabeth Holmes is the convicted former CEO at Theranos, a now-defunct blood test company.
Holmes was a charming and charismatic leader, poised to change the world of clinical laboratory testing. Her legacy, however, will instead be one of enamoring well-recognized investors with her personality while the technology behind her company ultimately proved lacking.
Her downfall was stunning. In 2014, Holmes was reported to have 18 U.S. patents and 66 non-U.S. patents in her name, and she was listed as a co-inventor on more than 100 patent applications. She was the youngest self-made female billionaire on the 2014 Forbes 400 list, with an estimated net worth of $4.6 billion. Yet by early 2016, Forbes updated her net worth to zero.
She founded Theranos in 2003 at age 19 while she was a chemical engineering major at Stanford University. She subsequently dropped out of Stanford as a sophomore to focus on her startup.
Theranos’ technology was based on her invention and patent for a way to run 30 common clinical laboratory tests on blood obtained via a fingerstick using microfluidics technology – a much faster and cheaper method than traditional lab testing techniques.
By 2014, the company offered 200 tests, was licensed to operate in every state in the U.S., and was valued at nearly $10 billion.
While some observers predicted Holmes’s innovations would dominate the clinical lab test market, an in-depth investigative report by The Wall Street Journal in October 2015 revealed aspects of Theranos that the secretive company has kept from public view. This reporting started the chain of events that would lead to Theranos’s downfall.
As a result of regulator scrutiny, in July 2016, the Medicare program handed down stringent sanctions to Theranos for problems at the company’s lab, including a two-year prohibition on Holmes owning any CLIA-certified laboratory.
Then, in March 2018, the U.S. Security and Exchange Commission (SEC) filed charges that focused on Theranos and Holmes allegedly raising more than $700 million from investors by exaggerating or making false statements about the company’s technology and financial performance.
To settle the SEC’s charges, Holmes agreed to pay a $500,000 fine and surrender almost 19 million shares of Theranos stock and voting control of the company, the SEC said. Also, she was barred from running a public company for 10 years. At the time, Holmes did not admit to nor deny the charges.
Later in 2018, the federal prosecutors charged Holmes on various counts of conspiracy and wire fraud charges. Following the indictments, Holmes stepped down as CEO. Theranos dissolved in September 2018.
Holmes went on trial in fall 2021 after multiple delays due to the COVID-19 pandemic and her pregnancy. On January 3, 2022, she was found guilty on three counts of defrauding investors and one count of wire fraud. She is scheduled to be sentenced in September 2022.
Theranos Lays Off More Staff, Voids More Lab Test Results
ONCE AGAIN, the controversial lab testing company, Theranos, Inc., found itself the subject of negative news stories. In recent weeks, The Wall Street Journal reported that the beleaguered lab testing company in Palo Alto, Calif., laid off 155 staffers, voided more laboratory test results, a…
Much Disruption for Labs In 2016’s Top 10 Stories
CEO SUMMARY: Within THE DARK REPORT’S list of the Top 10 Lab Industry Stories for 2016 is one story of disruption that might have been one story of disruption about to happen. The disintegration of Theranos during 2016 is the big story about a self-proclaimed disruptor of the lab indust…
Theranos Ends Patient Testing, Sued for Deceiving Investors
IN THE EARLY 1960S, the great bluesman Albert King wrote, “Born Under a Bad Sign,” which contained the unforgettable lyric, “If it wasn’t for bad luck, I wouldn’t have no luck at all.” That lyric almost describes what’s happened to Theranos Inc. since October 2015. Al…
Score for Theranos after AACC: Fail.
This is an excerpt from a 1,600-word article in the August 15 issue of THE DARK REPORT. The complete article is available to paid members of the Dark Intelligence Group. …
Elizabeth Holmes of Theranos Speaks at AACC To Skeptical PhDs, Pathologists, and Press
CEO SUMMARY: Elizabeth Holmes, Founder and CEO of Theranos, Inc., was given the ideal platform by AACC to show the science behind her lab company’s much-touted diagnostic technologies. But in a surprise to the assembled audience, Holmes, accompanied by three PhDs on her team, chose to d…
What will the future hold for Theranos?
This is an excerpt from a 1,900-word article in the July 25 issue of THE DARK REPORT. The complete article is available to paid members of the Dark Intelligence Group. …
CMS CLIA Sanction Letter Sent To Theranos Raises Questions
CITING PRACTICES THAT JEOPARDIZE PATIENT SAFETY, the federal Centers for Medicare & Medicaid Services decided earlier this month to revoke the CLIA certificate that it granted to Theranos Inc. to operate a clinical laboratory in Newark, Calif., and to ban the lab…
Theranos Now Scrambling To Save What It Can
CEO SUMMARY: On July 7, CMS imposed severe sanctions on Theranos for CLIA violations. Included is a two-year ban on owning and operating a clinical laboratory for Theranos, CEO Elizabeth Holmes, the former COO, and the former medical director. Theranos appears to be pivoting away from a c…
July 5, 2016 Intelligence: Late Breaking Lab News
More developments have happened at Theranos, Inc., the beleaguered clinical lab company based in Palo Alto, California. On June 24, Brook Buchanan, Vice President of Communications at Theranos, resigned, giving personal reasons for the decision. Buchanan was hired in November 2015, …
Up to 30,000 Theranos test results voided; Walgreen dumps partnership
This is an excerpt from a 1,000-word article in the June 13 issue of THE DARK REPORT. The original article is available to paid members of the Dark Intelligence Group. …
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.